Short Interest in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Decreases By 31.1%

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 57,500 shares, a decrease of 31.1% from the January 31st total of 83,500 shares. Based on an average daily volume of 636,200 shares, the short-interest ratio is currently 0.1 days. Currently, 2.1% of the company’s shares are sold short.

Sunshine Biopharma Trading Up 0.9 %

Shares of NASDAQ:SBFM traded up $0.02 during trading on Monday, hitting $2.31. 22,896 shares of the company were exchanged, compared to its average volume of 279,826. Sunshine Biopharma has a fifty-two week low of $2.11 and a fifty-two week high of $285.00. The stock has a market cap of $2.83 million, a price-to-earnings ratio of -0.02 and a beta of 1.33. The firm has a fifty day moving average price of $2.77 and a two-hundred day moving average price of $2.84.

Analysts Set New Price Targets

Separately, Aegis reissued a “buy” rating and set a $15.00 target price on shares of Sunshine Biopharma in a research note on Thursday, December 5th.

Institutional Investors Weigh In On Sunshine Biopharma

An institutional investor recently bought a new position in Sunshine Biopharma stock. Connective Capital Management LLC bought a new stake in Sunshine Biopharma, Inc. (NASDAQ:SBFM) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned 0.93% of Sunshine Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.